Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infants.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Bronchopulmonary dysplasia (BPD) is a respiratory dysfunction caused by poor lung bronchial development, which may lead to long-term lung disease, threatening the lives of children.

Firstly, a larger sample size will be needed to be included to gain a comprehensive understanding of the protective effects of vitamin D and BPD mechanistically in preterm infants.

Who Took Part

The study group was 112 infants.

The age groups tagged for this paper are infants and children.

A total of 112 preterm infants were randomly divided into two groups: the control and vitamin D supplementation (VD) group.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

The serum levels of 25(OH)D3 and C-reactive protein (CRP), IL6, and TNF-α were measured using ELISA assay.

The arterial partial pressure of oxygen (PaO2 ) and carbon dioxide (PaCO2 ) was measured using an i-STAT analyzer.

What Was Measured

PubMed files the paper under topics including Bronchopulmonary Dysplasia, Dietary Supplements, Infant, Premature, Interleukin-6, Tumor Necrosis Factor-alpha, Vitamin D and Vitamins.

The authors tagged it with the keywords bronchopulmonary dysplasia (BPD) and preterm infants.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 112 infants.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Pediatric pulmonology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.